Q2 EPS Estimate for Viridian Therapeutics Cut by Analyst

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for Viridian Therapeutics in a note issued to investors on Wednesday, May 7th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($1.09) per share for the quarter, down from their previous forecast of ($0.99). HC Wainwright currently has a "Buy" rating and a $34.00 price target on the stock. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics' Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.91) EPS, Q2 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.09) EPS, FY2027 earnings at ($2.84) EPS, FY2028 earnings at ($1.82) EPS and FY2029 earnings at ($0.01) EPS.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. The company's quarterly revenue was up .0% compared to the same quarter last year.

A number of other research firms also recently commented on VRDN. Needham & Company LLC decreased their target price on Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. JMP Securities cut their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Royal Bank of Canada dropped their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group dropped their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $36.70.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN traded up $0.73 during mid-day trading on Friday, reaching $13.12. The company's stock had a trading volume of 942,955 shares, compared to its average volume of 1,196,147. The firm has a market capitalization of $1.07 billion, a PE ratio of -3.04 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a fifty day moving average of $13.71 and a two-hundred day moving average of $17.44. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $27.20.

Hedge Funds Weigh In On Viridian Therapeutics

Several institutional investors have recently modified their holdings of the business. Loomis Sayles & Co. L P acquired a new position in shares of Viridian Therapeutics during the fourth quarter worth $26,845,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Viridian Therapeutics by 2,847.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company's stock valued at $25,436,000 after buying an additional 1,281,799 shares during the last quarter. Deep Track Capital LP raised its holdings in shares of Viridian Therapeutics by 20.6% in the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock valued at $86,701,000 after buying an additional 771,796 shares during the last quarter. FMR LLC raised its holdings in shares of Viridian Therapeutics by 6.2% in the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock valued at $227,776,000 after buying an additional 698,434 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its holdings in Viridian Therapeutics by 155.9% during the fourth quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company's stock worth $20,850,000 after purchasing an additional 662,634 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.